Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/3888
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | - |
dc.contributor.author | PAQUIN-PROULX, Dominic | - |
dc.contributor.author | SANTOS, Bianca A. N. | - |
dc.contributor.author | CARVALHO, Karina I. | - |
dc.contributor.author | TOLEDO-BARROS, Myrthes | - |
dc.contributor.author | OLIVEIRA, Ana Karolina Barreto de | - |
dc.contributor.author | KOKRON, Cristina M. | - |
dc.contributor.author | KALIL, Jorge | - |
dc.contributor.author | MOLL, Markus | - |
dc.contributor.author | KALLAS, Esper G. | - |
dc.contributor.author | SANDBERG, Johan K. | - |
dc.date.accessioned | 2014-01-28T22:17:14Z | - |
dc.date.available | 2014-01-28T22:17:14Z | - |
dc.date.issued | 2013 | - |
dc.identifier.citation | PLOS ONE, v.8, n.10, article ID e75199, 9p, 2013 | - |
dc.identifier.issn | 1932-6203 | - |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/3888 | - |
dc.description.abstract | Common variable immunodeficiency (CVID) is characterized by defective B cell function, impaired antibody production, and increased susceptibility to bacterial infections. Here, we addressed the hypothesis that poor antibody-mediated immune control of infections may result in substantial perturbations in the T cell compartment. Newly diagnosed CVID patients were sampled before, and 6-12 months after, initiation of intravenous immunoglobulin (IVIg) therapy. Treatment-naive CVID patients displayed suppressed CD4 T cell counts and myeloid dendritic cell (mDC) levels, as well as high levels of immune activation in CD8 T cells, CD4 T cells, and invariant natural killer T (iNKT) cells. Expression of co-stimulatory receptors CD80 and CD83 was elevated in mDCs and correlated with T cell activation. Levels of both FoxP3+ T regulatory (Treg) cells and iNKT cells were low, whereas soluble CD14 (sCD14), indicative of monocyte activation, was elevated. Importantly, immune reconstitution treatment with IVIg partially restored the CD4 T cell and mDC compartments. Treatment furthermore reduced the levels of CD8 T cell activation and mDC activation, whereas levels of Treg cells and iNKT cells remained low. Thus, primary deficiency in humoral immunity with impaired control of microbial infections is associated with significant pathological changes in cell-mediated immunity. Furthermore, therapeutic enhancement of humoral immunity with IVIg infusions alleviates several of these defects, indicating a relationship between poor antibody-mediated immune control of infections and the occurrence of abnormalities in the T cell and mDC compartments. These findings help our understanding of the immunopathogenesis of primary immunodeficiency, as well as acquired immunodeficiency caused by HIV-1 infection. | - |
dc.description.sponsorship | Swedish Research Council | - |
dc.description.sponsorship | Swedish Cancer Foundation | - |
dc.description.sponsorship | Stockholm County Council | - |
dc.description.sponsorship | Karolinska Institutet | - |
dc.description.sponsorship | US National Institutes of Health (NIH) [AI52731] | - |
dc.description.sponsorship | Canadian Institutes of Health Research | - |
dc.description.sponsorship | Conselho Nacional de Pesquisa (CNPq), Brazilian Ministry of Science and Technology | - |
dc.description.sponsorship | Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) through the PNPD Program, Brazilian Ministry of Education | - |
dc.description.sponsorship | CNPq | - |
dc.language.iso | eng | - |
dc.publisher | PUBLIC LIBRARY SCIENCE | - |
dc.relation.ispartof | Plos One | - |
dc.rights | openAccess | - |
dc.subject.other | common variable immunodeficiency | - |
dc.subject.other | cd1d-restricted nkt cells | - |
dc.subject.other | virus type-1 infection | - |
dc.subject.other | intravenous immunoglobulin | - |
dc.subject.other | hiv-1 infection | - |
dc.subject.other | microbial translocation | - |
dc.subject.other | replacement therapy | - |
dc.subject.other | dendritic cells | - |
dc.subject.other | disease progression | - |
dc.subject.other | individuals | - |
dc.title | IVIg Immune Reconstitution Treatment Alleviates the State of Persistent Immune Activation and Suppressed CD4 T Cell Counts in CVID | - |
dc.type | article | - |
dc.rights.holder | Copyright PUBLIC LIBRARY SCIENCE | - |
dc.identifier.doi | 10.1371/journal.pone.0075199 | - |
dc.identifier.pmid | 24130688 | - |
dc.subject.wos | Multidisciplinary Sciences | - |
dc.type.category | original article | - |
dc.type.version | publishedVersion | - |
hcfmusp.author.external | PAQUIN-PROULX, Dominic:Karolinska Univ, Huddinge Hosp, Karolinska Inst, Ctr Infect Med,Dept Med, Stockholm, Sweden | - |
hcfmusp.author.external | MOLL, Markus:Karolinska Univ, Huddinge Hosp, Karolinska Inst, Ctr Infect Med,Dept Med, Stockholm, Sweden | - |
hcfmusp.author.external | SANDBERG, Johan K.:Karolinska Univ, Huddinge Hosp, Karolinska Inst, Ctr Infect Med,Dept Med, Stockholm, Sweden | - |
hcfmusp.description.articlenumber | e75199 | - |
hcfmusp.description.issue | 10 | - |
hcfmusp.description.volume | 8 | - |
hcfmusp.origem | WOS | - |
hcfmusp.origem.id | 2-s2.0-84885161896 | - |
hcfmusp.origem.id | WOS:000325810900021 | - |
hcfmusp.publisher.city | SAN FRANCISCO | - |
hcfmusp.publisher.country | USA | - |
hcfmusp.relation.reference | Aukrust P, 1997, J INFECT DIS, V176, P913 | - |
hcfmusp.relation.reference | Ballow M, 2011, CLIN IMMUNOL, V139, P208, DOI 10.1016/j.clim.2011.02.006 | - |
hcfmusp.relation.reference | Barbosa RR, 2012, CLIN EXP IMMUNOL, V169, P263, DOI 10.1111/j.1365-2249.2012.04620.x | - |
hcfmusp.relation.reference | Barron MA, 2003, J INFECT DIS, V187, P26, DOI 10.1086/345957 | - |
hcfmusp.relation.reference | Bayry J, 2003, BLOOD, V101, P758, DOI 10.1182/blood-2002-05-1447 | - |
hcfmusp.relation.reference | Brenchley JM, 2012, ANNU REV IMMUNOL, V30, P149, DOI 10.1146/annurev-immunol-020711-075001 | - |
hcfmusp.relation.reference | Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511 | - |
hcfmusp.relation.reference | Carvalho KI, 2010, PLOS ONE, V5 | - |
hcfmusp.relation.reference | Cunningham-Rundles C, 2010, BLOOD, V116, P7, DOI 10.1182/blood-2010-01-254417 | - |
hcfmusp.relation.reference | Deeks SG, 2004, BLOOD, V104, P942, DOI 10.1182/blood-2003-09-3333 | - |
hcfmusp.relation.reference | Donaghy H, 2001, BLOOD, V98, P2574, DOI 10.1182/blood.V98.8.2574 | - |
hcfmusp.relation.reference | Eggena MP, 2005, J IMMUNOL, V174, P4407 | - |
hcfmusp.relation.reference | Eller MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018779 | - |
hcfmusp.relation.reference | Gelfand EW, 2012, NEW ENGL J MED, V367, P2015, DOI 10.1056/NEJMra1009433 | - |
hcfmusp.relation.reference | Genre J, 2009, CLIN IMMUNOL, V132, P215, DOI 10.1016/j.clim.2009.03.519 | - |
hcfmusp.relation.reference | GIORGI JV, 1989, CLIN IMMUNOL IMMUNOP, V52, P10, DOI 10.1016/0090-1229(89)90188-8 | - |
hcfmusp.relation.reference | Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660 | - |
hcfmusp.relation.reference | Giovannetti A, 2007, J IMMUNOL, V178, P3932 | - |
hcfmusp.relation.reference | Gouilleux-Gruart V, 2013, CLIN EXP IMMUNOL, V171, P186, DOI 10.1111/cei.12002 | - |
hcfmusp.relation.reference | Grassi F, 1999, AIDS, V13, P759, DOI 10.1097/00002030-199905070-00004 | - |
hcfmusp.relation.reference | Hazenberg MD, 2003, AIDS, V17, P1881, DOI 10.1097/01.aids.0000076311.76477.6e | - |
hcfmusp.relation.reference | Hunt PW, 2008, J INFECT DIS, V197, P126, DOI 10.1086/524143 | - |
hcfmusp.relation.reference | Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623 | - |
hcfmusp.relation.reference | Kasztalska K, 2011, CLIN DRUG INVEST, V31, P299, DOI 10.2165/11586710-000000000-00000 | - |
hcfmusp.relation.reference | Kaufmann DE, 2009, J IMMUNOL, V182, P5891, DOI 10.4049/jimmunol.0803771 | - |
hcfmusp.relation.reference | Kaufmann DE, 2007, NAT IMMUNOL, V8, P1246, DOI 10.1038/ni1515 | - |
hcfmusp.relation.reference | Kaveri SV, 2011, CLIN EXP IMMUNOL, V164, P2, DOI 10.1111/j.1365-2249.2011.04387.x | - |
hcfmusp.relation.reference | Khaitan Alka, 2011, Curr HIV/AIDS Rep, V8, P4, DOI 10.1007/s11904-010-0066-0 | - |
hcfmusp.relation.reference | Klatt NR, 2012, TRENDS MICROBIOL | - |
hcfmusp.relation.reference | Leeansyah E, 2013, CURR OPIN HIV AIDS, V8, P117, DOI 10.1097/COH.0b013e32835c7134 | - |
hcfmusp.relation.reference | Litzman J, 2012, CLIN EXP IMMUNOL, V170, P321, DOI 10.1111/j.1365-2249.2012.04655.x | - |
hcfmusp.relation.reference | Melo KM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006269 | - |
hcfmusp.relation.reference | Moll M, 2009, EUR J IMMUNOL, V39, P902, DOI 10.1002/eji.200838780 | - |
hcfmusp.relation.reference | Motsinger A, 2002, J EXP MED, V195, P869, DOI 10.1084/jem.20011712 | - |
hcfmusp.relation.reference | Ndhlovu LC, 2008, J LEUKOCYTE BIOL, V83, P254, DOI 10.1189/jlb.0507281 | - |
hcfmusp.relation.reference | Nordoy I, 1998, CLIN EXP IMMUNOL, V114, P258 | - |
hcfmusp.relation.reference | Park MA, 2008, LANCET, V372, P489, DOI 10.1016/S0140-6736(08)61199-X | - |
hcfmusp.relation.reference | Salzer U, 2012, ANN NY ACAD SCI, V1250, P41, DOI 10.1111/j.1749-6632.2011.06377.x | - |
hcfmusp.relation.reference | Sandberg JK, 2002, J VIROL, V76, P7528, DOI 10.1128/JVI.76.15.7528-7534.2002 | - |
hcfmusp.relation.reference | Sandberg JK, 2005, TRENDS IMMUNOL, V26, P347, DOI 10.1016/j.it.2005.05.006 | - |
hcfmusp.relation.reference | Sandler NG, 2012, NAT REV MICROBIOL, V10, P655, DOI 10.1038/nrmicro2848 | - |
hcfmusp.relation.reference | Shulzhenko N, 2011, NAT MED, V17, P1585, DOI 10.1038/nm.2505 | - |
hcfmusp.relation.reference | Van Kaer L, 2012, TRENDS IMMUNOL | - |
hcfmusp.relation.reference | van der Vliet HJJ, 2002, J IMMUNOL, V168, P1490 | - |
hcfmusp.relation.reference | Vermeulen JN, 2007, AIDS RES HUM RETROV, V23, P1348, DOI 10.1089/aid.2006.0210 | - |
hcfmusp.relation.reference | Young GR, 2012, NATURE, V491, P774, DOI 10.1038/nature11599 | - |
dc.description.index | MEDLINE | - |
hcfmusp.remissive.sponsorship | CAPES | - |
hcfmusp.remissive.sponsorship | CIHR | - |
hcfmusp.remissive.sponsorship | CNPq | - |
hcfmusp.remissive.sponsorship | NIH | - |
hcfmusp.citation.scopus | 44 | - |
hcfmusp.scopus.lastupdate | 2024-04-12 | - |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - FM/MCM Artigos e Materiais de Revistas Científicas - HC/ICHC Artigos e Materiais de Revistas Científicas - HC/InCor Artigos e Materiais de Revistas Científicas - LIM/19 Artigos e Materiais de Revistas Científicas - LIM/60 Artigos e Materiais de Revistas Científicas - ODS/03 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_SANTOS_IVIg_Immune_Reconstitution_Treatment_Alleviates_the_State_of_2013.PDF | publishedVersion (English) | 1.13 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.